自动化高通量筛选发现新型宫颈癌放疗增敏剂二氢哇巴因
本研究建立自动化高通量筛选平台,从LOPAC1280化合物库中筛选宫颈癌放疗增敏剂,鉴定出4个命中化合物;其中二氢哇巴因(DHO)通过抑制Chk1、增加DNA双链断裂并消除辐射诱导的S期阻滞,显著增强宫颈癌细胞放疗敏感性。
要点
- 自动化高通量筛选平台可有效鉴定宫颈癌放疗增敏候选化合物。
- DHO是Na+/K+-ATP酶抑制剂,此前未被归类为放疗增敏剂。
- DHO通过抑制Chk1、增加DNA双链断裂增强放疗敏感性。
核心结论
- DHO是治疗宫颈癌的新型放疗增敏剂。
- 本研究的自动化高通量筛选平台强大有效,未来有望广泛用于放疗增敏剂鉴定。
研究设计与样本
- 基于高通量筛选技术建立宫颈癌放疗增敏剂自动化鉴定平台。
- 使用克隆形成存活实验在放射敏感和放射抗拒宫颈癌细胞中评估LOPAC1280化合物库候选化合物的放疗增敏效应。
- 对两种细胞系进行细胞周期分析和蛋白质印迹分析。
主要发现
- 自动化高通量筛选鉴定出4个命中化合物。
- DHO是Na+/K+-ATP酶抑制剂,此前未被归类为放疗增敏剂。
- DHO显著增强宫颈癌细胞放射敏感性。
- DHO消除辐射诱导的宫颈癌细胞S期阻滞。
- 联合治疗显著抑制Chk1并增加DNA双链断裂。
临床怎么用
- DHO可作为宫颈癌放疗增敏的候选化合物进一步研究。
- 该自动化高通量筛选平台可用于未来放疗增敏剂的发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Radiotherapy plays a crucial role in the treatment of cervical cancer, but existing radiosensitizers have limited efficacy in clinical applications. The aims of this study were to establish and verify an efficient method for identifying new radiosensitizers, to use this to identify candidate radiosensitizers for cervical cancer, and to investigate the specific mechanisms of these when used in combination with radiotherapy. MATERIALS AND METHODS: An automated platform for identifying radiosensitizers for cervical cancer was created based on high-throughput screening technology. The radiosensitizing effects of candidate compounds from the LOPAC1280 chemical library were evaluated in radiosensitive and radioresistant cervical cancer cells using a clonogenic survival assay, with cell cycle analyses, and western blot analyses performed for both cell lines. RESULTS: The automated high-throughput screening approach identified four hit compounds. One of the most potent candidates was dihydroouabain (DHO), an inhibitor of Na+/K+-ATPase that has not previously been classified as a radiosensitizer. DHO significantly enhanced radiosensitivity in cervical cancer cells. It also abrogated radiation-induced S phase arrest in cervical cancer cells. Combination treatment significantly caused the inhibition of Chk1 and increased DNA double-strand breaks (DSB). CONCLUSIONS: DHO is a novel radiosensitizer for the treatment of cervical cancer. The automated high-throughput screening platform developed in this study proved to be powerful and effective, with the potential to be widely used in the future identification of radiosensitizers.
引用
- Li Z, Tamari K, Seo Y, et al. Dihydroouabain, a novel radiosensitizer for cervical cancer identified by automated high-throughput screening. Radiother Oncol. 2020. PMID: 32311597. doi:10.1016/j.radonc.2020.03.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。